Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Mechanism-based PK-PD models differ from conventional PK-PD models in that they contain specific expressions to characterize, in a quantitative manner, processes on the causal path between drug administration and effect. This includes target site distribution, target binding and activation, pharmacodynamic interactions, transduction, and homeostatic feedback mechanisms. As the final step, the effects on disease processes and disease progression are considered. Particularly through the incorporation of concepts from receptor theory and dynamical systems analysis, important progress has been made in the field of mechanism-based PK-PD modeling. This has yielded models with much-improved properties for extrapolation and prediction. These models constitute a theoretical basis for rational drug discovery and development.

[1]  M. Danhof,et al.  Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo , 2000, Pharmaceutical Research.

[2]  J. Mandema,et al.  Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.

[3]  R. Bendayan,et al.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.

[4]  P. Gaillard,et al.  The role of drug transporters at the blood-brain barrier. , 2003, Annual review of pharmacology and toxicology.

[5]  M O Karlsson,et al.  A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. , 2000, The Journal of pharmacology and experimental therapeutics.

[6]  D R Stanski,et al.  EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. , 1985, Anesthesiology.

[7]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[8]  F. Ehlert,et al.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.

[9]  W. Sieghart GABAA receptors: ligand-gated Cl- ion channels modulated by multiple drug-binding sites. , 1992, Trends in pharmacological sciences.

[10]  J. Nedelman,et al.  Physiologically based pharmacokinetic modeling as a tool for drug development , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  Meindert Danhof,et al.  Pharmacodynamic Analysis of the Interaction between Tiagabine and Midazolam with an Allosteric Model That Incorporates Signal Transduction , 2003, Epilepsia.

[12]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. , 1997, Journal of pharmacological and toxicological methods.

[13]  G. Martin,et al.  Estimation of agonist affinity and efficacy by direct, operational model-fitting. , 1990, Journal of pharmacological methods.

[14]  M. Danhof,et al.  Pharmacokinetic‐pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration , 1991, British journal of pharmacology.

[15]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[16]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[17]  Meindert Danhof,et al.  Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier , 1997, Brain Research Reviews.

[18]  Kinetics of combined drug action , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  P Veng-Pedersen,et al.  Pharmacodynamic system analysis of the biophase level predictor and the transduction function. , 1992, Journal of pharmaceutical sciences.

[20]  M. Danhof,et al.  Electroencephalogram Effect Measures and Relationships Between Pharmacokinetics and Pharmacodynamics of Centrally Acting Drugs , 1992, Clinical pharmacokinetics.

[21]  P K Gessner,et al.  Isobolographic analysis of interactions: an update on applications and utility. , 1995, Toxicology.

[22]  J. Bergh,et al.  Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[24]  M Danhof,et al.  Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[25]  C. T. Viswanathan,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.

[26]  J. A. Peters,et al.  Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors. , 1997, Journal of medicinal chemistry.

[27]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[28]  L. Peletier,et al.  Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.

[29]  L B Sheiner,et al.  Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.

[30]  M Danhof,et al.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration‐EEG effect relationship , 1992, British journal of pharmacology.

[31]  R. Barlow,et al.  The affinity and efficacy of onium salts on the frog rectus abdominis. , 1967, British journal of pharmacology and chemotherapy.

[32]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[33]  D. Jonker,et al.  A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data , 2005, Clinical pharmacology and therapeutics.

[34]  Meindert Danhof,et al.  A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. , 2002, The Journal of pharmacology and experimental therapeutics.

[35]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[36]  N. Modi,et al.  A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil. , 1993, Journal of pharmaceutical sciences.

[37]  M. Danhof,et al.  Influence of Different Fat Emulsion-Based Intravenous Formulations on the Pharmacokinetics and Pharmacodynamics of Propofol , 1998, Pharmaceutical Research.

[38]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[39]  Berenbaum Mc What is synergy? , 1989, Pharmacological reviews.

[40]  Peter Veng-Pedersen,et al.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[41]  M. Danhof,et al.  The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. , 1999, Anesthesiology.

[42]  Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A1‐receptor agonist N6‐(p‐sulphophenyl)adenosine in rats , 1997, British journal of pharmacology.

[43]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[44]  T. Lewander,et al.  Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin. , 1996, European journal of pharmacology.

[45]  K. Zuideveld,et al.  Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  M Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. , 1991, The Journal of pharmacology and experimental therapeutics.

[47]  M Danhof,et al.  Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. , 1999, The Journal of pharmacology and experimental therapeutics.

[48]  J. Šterc Recent studies of hypothalamic function: K. Lederis and K.E. Cooper (Editors). Proceedings of the International Symposium, Calgary, 1973. (S. Karger, Basel, 1974, 434 p., 137 Fig., 17 Tables, DM 128.00, U.S. $49.25). , 1976 .

[49]  M Danhof,et al.  A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. , 1991, Journal of pharmaceutical sciences.

[50]  Meindert Danhof,et al.  Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[51]  M. Danhof,et al.  In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.

[52]  Jin Y. Jin,et al.  Modeling of Corticosteroid Pharmacogenomics in Rat Liver Using Gene Microarrays , 2003, Journal of Pharmacology and Experimental Therapeutics.

[53]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[54]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[55]  M. Danhof,et al.  Quantification of the EEG Effect of Midazolam by Aperiodic Analysis in Volunteers , 1990, Clinical pharmacokinetics.

[56]  M. Danhof,et al.  5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization , 2007 .

[57]  E. Ekblad,et al.  A model eliciting transient responses. , 1984, The American journal of physiology.

[58]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[59]  M. Danhof,et al.  Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. , 1995, Life sciences.

[60]  W. Jusko,et al.  Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. , 2004, Journal of veterinary pharmacology and therapeutics.

[61]  L. D. van de Kar,et al.  Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. , 1996, The Journal of pharmacology and experimental therapeutics.

[62]  L. Peletier,et al.  A Pharmacodynamic Turnover Model Capturing Asymmetric Circadian Baselines of Body Temperature, Heart Rate and Blood Pressure in Rats: Challenges in Terms of Tolerance and Animal-handling Effects , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[63]  A. G. de Boer,et al.  The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice , 1999, British Journal of Pharmacology.

[64]  P H van der Graaf,et al.  A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[65]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.

[66]  L. Peletier,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. , 2002, The Journal of pharmacology and experimental therapeutics.

[67]  S L Shafer,et al.  Response Surface Model for Anesthetic Drug Interactions , 2000, Anesthesiology.

[68]  K. Brouwer,et al.  Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat , 1998, Pharmaceutical Research.

[69]  John Anthony Bauer,et al.  Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.

[70]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[71]  M. Hammarlund-Udenaes The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. , 2000, Advanced drug delivery reviews.

[72]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[73]  S. Visser,et al.  Rapid and long-lasting tolerance to clomethiazole-induced hypothermia in the rat. , 2005, European journal of pharmacology.

[74]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[75]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[76]  L. Paalzow,et al.  Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis Method , 1997, Pharmaceutical Research.

[77]  Jin Y. Jin,et al.  Receptor/Gene-Mediated Pharmacodynamic Effects of Methylprednisolone on Phosphoenolpyruvate Carboxykinase Regulation in Rat Liver , 2004, Journal of Pharmacology and Experimental Therapeutics.

[78]  L. Peletier,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[79]  W. H. Carter Relating isobolograms to response surfaces. , 1995, Toxicology.

[80]  Ariens Ej,et al.  A theoretical basis of molecular pharmacology. I. Interactions of one or two compounds with one receptor system. , 1956 .

[81]  James C. Scott,et al.  Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. , 1991, Anesthesiology.

[82]  M. Danhof,et al.  Pharmacokinetic‐pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation , 1998, British journal of pharmacology.

[83]  Meindert Danhof,et al.  Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.

[84]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.

[85]  E. Zeisberger Chapter 10 Biogenic amines and thermoregulatory changes , 1998 .

[86]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[87]  J. Steimer,et al.  A mathematical model for dynamics of cardiovascular drug action: Application to intravenous dihydropyridines in healthy volunteers , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[88]  Meindert Danhof,et al.  Disease System Analysis: Basic Disease Progression Models in Degenerative Disease , 2005, Pharmaceutical Research.

[89]  M. Danhof,et al.  Pharmacokinetic-Pharmacodynamic Modelling of the Interaction between Flumazenil and Midazolam in Volunteers by Aperiodic EEG Analysis , 1991, Clinical pharmacokinetics.

[90]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. , 1994, The Journal of pharmacology and experimental therapeutics.

[91]  M. Danhof,et al.  Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. , 1996, Journal of Pharmacology and Experimental Therapeutics.

[92]  M. Danhof,et al.  Selectivity of action of 8‐alkylamino analogues of N6‐cyclopentyladenosine in vivo: haemodynamic versus anti‐lipolytic responses in rats , 1998, British journal of pharmacology.

[93]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.

[94]  L. Sheiner,et al.  Pharmacokinetics and Pharmacodynamics of d-Tubocurarine during Nitrous Oxide–Narcotic and Halothane Anesthesia in Man , 1979 .

[95]  D J Greenblatt,et al.  Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines , 1996, Clinical pharmacokinetics.

[96]  M. Danhof,et al.  Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-Receptor Agonists , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[97]  M. Danhof,et al.  Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6‐cyclopentyladenosine and 8‐cyclopentyltheophylline , 1995, British journal of pharmacology.

[98]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[99]  M. Danhof,et al.  Mechanism-Based Pharmacodynamic Modeling of the Interaction of Midazolam, Bretazenil, and Zolpidem with Ethanol , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[100]  M. R. Bouw,et al.  Blood‐brain barrier transport and brain distribution of morphine‐6‐glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling , 2001, British journal of pharmacology.

[101]  L. Peletier,et al.  Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. , 2002, European journal of pharmacology.

[102]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[103]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[104]  L. Peletier,et al.  Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo , 2002, Journal of Pharmacology and Experimental Therapeutics.

[105]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[106]  M. Danhof,et al.  Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo , 1995, British journal of pharmacology.

[107]  W. Winter,et al.  A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[108]  J. Urquhart,et al.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans , 1987, Clinical pharmacology and therapeutics.

[109]  R. Ramakrishnan,et al.  Fifth-Generation Model for Corticosteroid Pharmacodynamics: Application to Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[110]  M Danhof,et al.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations , 2003, Journal of Pharmacology and Experimental Therapeutics.

[111]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[112]  Adriaan Cleton,et al.  Application of a Combined “Effect Compartment/Indirect Response Model” to the Central Nervous System Effects of Tiagabine in the Rat , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[113]  Juliana Barr,et al.  Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers , 1996, Anesthesiology.

[114]  A. Schinkel,et al.  Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[115]  W. Haefely,et al.  The multiplicity of actions of benzodiazepine receptor ligands. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.